MGI Tech Co Documenten
Documenten
0
Ticker
688114.SS
ISIN
CNE100005PC8
MGI Tech Co SEC Filings
Type | Bericht | Datum |
|---|---|---|
| Geen documenten beschikbaar | ||
MGI Tech Co Documenten 2026
Deze pagina bevat alle officiële documenten en SEC-filings voor MGI Tech Co aandelen (688114.SS, ISIN: CNE100005PC8). Dit omvat jaarverslagen (Formulier 10-K), kwartaalrapporten (Formulier 10-Q) en insidertransacties (Formulier 4). Momenteel zijn 0 documenten beschikbaar. Gegevens worden regelmatig bijgewerkt om beleggers een volledig overzicht van MGI Tech Co's regelgevingsfilings te bieden.
MGI Tech Co Aandelenanalyse
MGI Tech Co MGI Tech Co., Ltd. generates revenue through the sale of DNA sequencing instruments, reagents, and related products for life science research, agriculture, precision medicine, and healthcare. The company's gene sequencer business offers desktop and large sequencers, creating a multi-model product range for diverse user needs. Laboratory automation products include automated sample processing systems, pipelines, and reagent consumables, targeting laboratories requiring efficient workflows. New business segments feature cytomic solutions, remote ultrasound robots, and bioinformation Technology (BIT) products, expanding into emerging applications. The primary customers are research institutions, agricultural companies, healthcare providers, and precision medicine facilities. These segments purchase the company's instruments, reagents, and automation systems to support their operations in genomics, diagnostics, and laboratory management. The gene sequencer and laboratory automation businesses form the core revenue streams, while new business products represent growth opportunities in innovative fields. MGI Tech's product portfolio spans multiple applications, with the gene sequencer business focusing on scalable sequencing solutions and laboratory automation addressing workflow efficiency. The new business segment introduces advanced technologies like remote ultrasound robots, targeting specialized healthcare environments. All products are sold directly to end-users in the specified sectors without mentioning third-party distributors or partners.